Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Share-based Compensation: 2019-2025

Historic Share-based Compensation for Benitec Biopharma (BNTC) over the last 7 years, with Jun 2025 value amounting to $17.4 million.

  • Benitec Biopharma's Share-based Compensation rose 1245.59% to $6.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $17.4 million, marking a year-over-year increase of 1999.52%. This contributed to the annual value of $17.4 million for FY2025, which is 1999.52% up from last year.
  • Latest data reveals that Benitec Biopharma reported Share-based Compensation of $17.4 million as of FY2025, which was up 1,999.52% from $830,000 recorded in FY2024.
  • In the past 5 years, Benitec Biopharma's Share-based Compensation ranged from a high of $17.4 million in FY2025 and a low of $452,000 during FY2023.
  • Moreover, its 3-year median value for Share-based Compensation was $830,000 (2024), whereas its average is $6.2 million.
  • Per our database at Business Quant, Benitec Biopharma's Share-based Compensation slumped by 48.05% in 2023 and then spiked by 1,999.52% in 2025.
  • Over the past 5 years, Benitec Biopharma's Share-based Compensation (Yearly) stood at $634,000 in 2021, then spiked by 37.22% to $870,000 in 2022, then slumped by 48.05% to $452,000 in 2023, then soared by 83.63% to $830,000 in 2024, then spiked by 1,999.52% to $17.4 million in 2025.